He previously served as senior vice president and division head at SeraCare Life Sciences’ Genomics Collaborative Division (GCI), where he managed all worldwide diagnostic and pharmaceutical R&D collaborations. Before GCI was acquired by Seracare Life Sciences, Krenitsky acted as the company’s medical director, responsible for spearheading the development of GCI’s global network of five hundred-plus clinical sites on four continents. During his tenure at GCI, Krenitsky was instrumental in developing several hundred agreements with dozens of major pharmaceutical, biotechnology, and diagnostic companies worldwide.
“Kevin’s impressive credentials in the clinical service, molecular diagnostics, and pre-clinical and clinical pharma, should serve us well as we continue to develop Enzo Clinical Labs into a molecular and esoteric center of excellence,” said Barry Weiner, president of Enzo Biochem “Kevin’s extensive operational experience along with his success in the launching of new service offerings will be instrumental in growing Enzo Clinical Labs.”